Market success in metabolic disease is likely to hinge on differentiated clinical profiles, delivery innovation (especially oral formulations), and payer-aligned value strategies
(Lausanne) 12 , 665537 (2021)
Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent
Clinical studies have shown that GLP-1 medications are highly effective for weight loss
Remarkably, there is evidence that GLP-1 agonists can enhance left ventricular ejection fraction, inotropy, coronary blood flow, cardiac output, and vascular endothelial function because of their cardiovascular effects and decrease overall cardiovascular event risks
This rapid breakdown severely limits its therapeutic potential in native form